Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
bimatoprost 20 µg generation 2 · 1 trial · 2 indications
IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
| Arm | Type | Description |
|---|---|---|
| bimatoprost 20 µg generation 2, bimatoprost 0.03% | OTHER | Single dose of bimatoprost ophthalmic 20 µg generation 2 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months. |
| bimatoprost 15 µg generation 2, bimatoprost 0.03% | OTHER | Single dose of bimatoprost ophthalmic 15 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months. |
| bimatoprost 10 µg generation 2, bimatoprost 0.03% | OTHER | Single dose of bimatoprost ophthalmic 10 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months. |
| bimatoprost 6 µg generation 2, bimatoprost 0.03% | OTHER | Single dose of bimatoprost ophthalmic 6 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months. |
| bimatoprost 15 µg generation 1, bimatoprost 0.03% | OTHER | Single dose of bimatoprost ophthalmic 15 µg generation 1 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months. |
| bimatoprost 10 µg generation 1, bimatoprost 0.03% | OTHER | Single dose of bimatoprost ophthalmic 10 µg generation 1 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months. |
| Name | Type | Description |
|---|---|---|
| bimatoprost 20 µg generation 2 | DRUG | Single dose of bimatoprost ophthalmic administered in the study eye on Day 1. |
| bimatoprost 15 µg generation 2 | DRUG | Single dose of bimatoprost ophthalmic administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). |
| bimatoprost 10 µg generation 2 | DRUG | Single dose of bimatoprost ophthalmic 10 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). |
| bimatoprost 6 µg generation 2 | DRUG | Single dose of bimatoprost ophthalmic 6 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). |
| bimatoprost 15 µg generation 1 | DRUG | Single dose of bimatoprost ophthalmic 15 µg generation 1 administered in the study eye on Day 1. |
| bimatoprost 10 µg generation 1 | DRUG | Single dose of bimatoprost ophthalmic 10 µg generation 1 administered in the study eye on Day 1. |
| bimatoprost 0.03% | DRUG | One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months. |
Inclusion Criteria: * Diagnosis of open angle glaucoma or ocular hypertension Exclusion Criteria: * Uncontrolled medical conditions * Anticipated wearing of contact lenses during the study
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |
Bimatoprost 20 µg generation 2 is an investigational small molecule being developed for the treatment of open-angle glaucoma. It is administered as an ophthalmic formulation. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Bimatoprost 20 µg generation 2 is being developed by AbbVie Inc. (NYSE: ABBV). The company is conducting clinical trials to evaluate the safety and efficacy of this ophthalmic formulation in patients with open-angle glaucoma and ocular hypertension.
Bimatoprost 20 µg generation 2 is in Phase 1 clinical development. One Phase 1 trial has been completed, involving 109 participants. The drug is investigational and has not yet received FDA approval.
Bimatoprost 20 µg generation 2 has one completed clinical trial, NCT01157364, titled "Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension." This Phase 1 study enrolled 109 participants across multiple countries.
Bimatoprost 20 µg generation 2 is a specific formulation of bimatoprost, a prostaglandin analog used to lower intraocular pressure. The "20 µg generation 2" designation refers to a particular ophthalmic formulation being developed by AbbVie for open-angle glaucoma.